Bolt Biotherapeutics (BOLT) - Total Assets
Based on the latest financial reports, Bolt Biotherapeutics (BOLT) holds total assets worth $56.75 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Bolt Biotherapeutics balance sheet quality to measure how much of total assets are equity-financed.
Bolt Biotherapeutics - Total Assets Trend (2018–2025)
This chart illustrates how Bolt Biotherapeutics's total assets have evolved over time, based on quarterly financial data. Explore BOLT long-term investment intensity to see how much of total assets are deployed in long-term investments.
Bolt Biotherapeutics - Asset Composition Analysis
Current Asset Composition (December 2025)
Bolt Biotherapeutics's total assets of $56.75 Million consist of 53.3% current assets and 46.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.6% |
| Accounts Receivable | $973.00K | 1.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Bolt Biotherapeutics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Bolt Biotherapeutics.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bolt Biotherapeutics's current assets represent 53.3% of total assets in 2025, a decrease from 88.3% in 2018.
- Cash Position: Cash and equivalents constituted 20.6% of total assets in 2025, down from 85.4% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 1.7% of total assets.
Bolt Biotherapeutics Competitors by Total Assets
Key competitors of Bolt Biotherapeutics based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Bolt Biotherapeutics - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.59 | 3.20 | 22.58 |
| Quick Ratio | 3.59 | 3.20 | 22.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $21.82 Million | $34.96 Million | $259.20 Million |
Bolt Biotherapeutics - Advanced Valuation Insights
This section examines the relationship between Bolt Biotherapeutics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.36 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | -43.0% |
| Total Assets | $56.75 Million |
| Market Capitalization | $8.09 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bolt Biotherapeutics's assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Bolt Biotherapeutics's assets decreased by 43.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bolt Biotherapeutics (2018–2025)
The table below shows the annual total assets of Bolt Biotherapeutics from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $56.75 Million | -43.04% |
| 2024-12-31 | $99.63 Million | -37.65% |
| 2023-12-31 | $159.78 Million | -29.86% |
| 2022-12-31 | $227.81 Million | -25.97% |
| 2021-12-31 | $307.72 Million | +561.16% |
| 2020-12-31 | $46.54 Million | -3.93% |
| 2019-12-31 | $48.45 Million | +203.27% |
| 2018-12-31 | $15.97 Million | -- |
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agon… Read more